WEKO3
アイテム
{"_buckets": {"deposit": "e362bac1-3671-43e6-8d54-66b989d84580"}, "_deposit": {"created_by": 2, "id": "9598", "owners": [2], "pid": {"revision_id": 0, "type": "depid", "value": "9598"}, "status": "published"}, "_oai": {"id": "oai:nagasaki-u.repo.nii.ac.jp:00009598", "sets": ["30"]}, "author_link": ["38778", "38781", "38776", "38772", "38779", "38780", "38768", "38773", "38774", "38769", "38777", "38775", "38770", "38771"], "item_2_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2012-09", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "5", "bibliographicPageEnd": "351", "bibliographicPageStart": "347", "bibliographicVolumeNumber": "13", "bibliographic_titles": [{"bibliographic_title": "Clinical Lung Cancer"}]}]}, "item_2_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "The safety and efficacy of platinum-based combination chemotherapy for elderly patients with advanced Non-Small-cell lung cancer (NSCLC) remains unclear. We conducted phase I and phase II trials of a combination of vinorelbine and carboplatin for patients \u003c75 years of age and with advanced NSCLC. Previously untreated patients (\u003c75 years of age) with stage IIIB or IV NSCLC were enrolled. Based on a 4-week cycle, vinorelbine was given on days 1 and 8, and carboplatin was given on day 1. Dose-limiting toxicity was defined as grade 4 hematologic toxicity that lasted 4 days or more, febrile neutropenia; grade 3 or worse nonhematologic toxicities; or the omission of vinorelbine administration on day 8 in the first cycle. Thirteen patients were enrolled in phase I. dose-limiting toxicity was grade 4 neutropenia that lasted 4 days or more, observed in 2 of 4 patients at level 4. Phase II study used the dose of level 3 (20 mg/m 2 vinorelbine, area under the curve of 4 mg/mL/min carboplatin). Forty-two patients were enrolled. The response rate was 14.6% of 41 assessable patients (95% CI, 3.8-25.4). The median time to progression was 98 days (95% CI, 61-135 days), and the median survival time was 366 days (95% CI, 321-411 days). All toxicities were mild and manageable. Use of 20 mg/m 2 vinorelbine on days 1 and 8, followed by carboplatin area under the curve of 4 mg/mL/min on day 1 every 4 weeks warrants a phase III study for elderly patients with advanced NSCLC.", "subitem_description_type": "Abstract"}]}, "item_2_description_63": {"attribute_name": "引用", "attribute_value_mlt": [{"subitem_description": "Clinical Lung Cancer, 13(5), pp.347-351; 2012", "subitem_description_type": "Other"}]}, "item_2_publisher_33": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "Elsevier"}]}, "item_2_relation_12": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type": "isVersionOf", "subitem_relation_type_id": {"subitem_relation_type_id_text": "10.1016/j.cllc.2011.11.007", "subitem_relation_type_select": "DOI"}}]}, "item_2_rights_13": {"attribute_name": "権利", "attribute_value_mlt": [{"subitem_rights": "© 2012 Elsevier Inc."}, {"subitem_rights": "NOTICE: this is the author’s version of a work that was accepted for publication in Clinical Lung Cancer. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in Clinical Lung Cancer, 13, 5(2012)"}]}, "item_2_source_id_7": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "15257304", "subitem_source_identifier_type": "ISSN"}]}, "item_2_version_type_16": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_ab4af688f83e57aa", "subitem_version_type": "AM"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Takatani, Hiroshi"}], "nameIdentifiers": [{"nameIdentifier": "38768", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nakamura, Yoichi"}], "nameIdentifiers": [{"nameIdentifier": "38769", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nagashima, Seiji"}], "nameIdentifiers": [{"nameIdentifier": "38770", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Soda, Hiroshi"}], "nameIdentifiers": [{"nameIdentifier": "38771", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kinoshita, Akitoshi"}], "nameIdentifiers": [{"nameIdentifier": "38772", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Fukuda, Minoru"}], "nameIdentifiers": [{"nameIdentifier": "38773", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Fukuda, Masaaki"}], "nameIdentifiers": [{"nameIdentifier": "38774", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Soejima, Yoshifumi"}], "nameIdentifiers": [{"nameIdentifier": "38775", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kasai, Takashi"}], "nameIdentifiers": [{"nameIdentifier": "38776", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nakatomi, Katsumi"}], "nameIdentifiers": [{"nameIdentifier": "38777", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Iida, Tetsuya"}], "nameIdentifiers": [{"nameIdentifier": "38778", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Oka, Mikio"}], "nameIdentifiers": [{"nameIdentifier": "38779", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Tsukamoto, Kazuhiro"}], "nameIdentifiers": [{"nameIdentifier": "38780", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kohno, Shigeru"}], "nameIdentifiers": [{"nameIdentifier": "38781", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2020-12-22"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "CLC13_347.pdf", "filesize": [{"value": "247.2 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 247200.0, "url": {"label": "CLC13_347.pdf", "url": "https://nagasaki-u.repo.nii.ac.jp/record/9598/files/CLC13_347.pdf"}, "version_id": "9e50e4aa-6168-4e3d-bae0-a0172c835647"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "Carboplatin", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Elderly patients", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Non-Small-cell lung cancer", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Vinorelbine", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Phase I and II Trials of Vinorelbine With Carboplatin for Patients 75 Years of Age or Older With Previously Untreated Non–Small-Cell Lung Cancer", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Phase I and II Trials of Vinorelbine With Carboplatin for Patients 75 Years of Age or Older With Previously Untreated Non–Small-Cell Lung Cancer"}]}, "item_type_id": "2", "owner": "2", "path": ["30"], "permalink_uri": "http://hdl.handle.net/10069/30241", "pubdate": {"attribute_name": "公開日", "attribute_value": "2013-01-16"}, "publish_date": "2013-01-16", "publish_status": "0", "recid": "9598", "relation": {}, "relation_version_is_last": true, "title": ["Phase I and II Trials of Vinorelbine With Carboplatin for Patients 75 Years of Age or Older With Previously Untreated Non–Small-Cell Lung Cancer"], "weko_shared_id": -1}
Phase I and II Trials of Vinorelbine With Carboplatin for Patients 75 Years of Age or Older With Previously Untreated Non–Small-Cell Lung Cancer
http://hdl.handle.net/10069/30241
http://hdl.handle.net/10069/302416ae10d95-bf9a-40a4-a2f8-cf7e15f63986
名前 / ファイル | ライセンス | アクション |
---|---|---|
CLC13_347.pdf (247.2 kB)
|
|
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2013-01-16 | |||||
タイトル | ||||||
タイトル | Phase I and II Trials of Vinorelbine With Carboplatin for Patients 75 Years of Age or Older With Previously Untreated Non–Small-Cell Lung Cancer | |||||
言語 | ||||||
言語 | eng | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Carboplatin | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Elderly patients | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Non-Small-cell lung cancer | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Vinorelbine | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
著者 |
Takatani, Hiroshi
× Takatani, Hiroshi× Nakamura, Yoichi× Nagashima, Seiji× Soda, Hiroshi× Kinoshita, Akitoshi× Fukuda, Minoru× Fukuda, Masaaki× Soejima, Yoshifumi× Kasai, Takashi× Nakatomi, Katsumi× Iida, Tetsuya× Oka, Mikio× Tsukamoto, Kazuhiro× Kohno, Shigeru |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | The safety and efficacy of platinum-based combination chemotherapy for elderly patients with advanced Non-Small-cell lung cancer (NSCLC) remains unclear. We conducted phase I and phase II trials of a combination of vinorelbine and carboplatin for patients <75 years of age and with advanced NSCLC. Previously untreated patients (<75 years of age) with stage IIIB or IV NSCLC were enrolled. Based on a 4-week cycle, vinorelbine was given on days 1 and 8, and carboplatin was given on day 1. Dose-limiting toxicity was defined as grade 4 hematologic toxicity that lasted 4 days or more, febrile neutropenia; grade 3 or worse nonhematologic toxicities; or the omission of vinorelbine administration on day 8 in the first cycle. Thirteen patients were enrolled in phase I. dose-limiting toxicity was grade 4 neutropenia that lasted 4 days or more, observed in 2 of 4 patients at level 4. Phase II study used the dose of level 3 (20 mg/m 2 vinorelbine, area under the curve of 4 mg/mL/min carboplatin). Forty-two patients were enrolled. The response rate was 14.6% of 41 assessable patients (95% CI, 3.8-25.4). The median time to progression was 98 days (95% CI, 61-135 days), and the median survival time was 366 days (95% CI, 321-411 days). All toxicities were mild and manageable. Use of 20 mg/m 2 vinorelbine on days 1 and 8, followed by carboplatin area under the curve of 4 mg/mL/min on day 1 every 4 weeks warrants a phase III study for elderly patients with advanced NSCLC. | |||||
書誌情報 |
Clinical Lung Cancer 巻 13, 号 5, p. 347-351, 発行日 2012-09 |
|||||
出版者 | ||||||
出版者 | Elsevier | |||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 15257304 | |||||
DOI | ||||||
関連タイプ | isVersionOf | |||||
識別子タイプ | DOI | |||||
関連識別子 | 10.1016/j.cllc.2011.11.007 | |||||
権利 | ||||||
権利情報 | © 2012 Elsevier Inc. | |||||
権利 | ||||||
権利情報 | NOTICE: this is the author’s version of a work that was accepted for publication in Clinical Lung Cancer. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in Clinical Lung Cancer, 13, 5(2012) | |||||
著者版フラグ | ||||||
出版タイプ | AM | |||||
出版タイプResource | http://purl.org/coar/version/c_ab4af688f83e57aa | |||||
引用 | ||||||
内容記述タイプ | Other | |||||
内容記述 | Clinical Lung Cancer, 13(5), pp.347-351; 2012 |